Day Traders Tag icon

×
Novo Nordisk A/S (NYSE:NVO) CEO Lars Fruergaard Jørgensen has defended the high U.S. prices of the company’s blockbuster drugs, Ozempic and Wegovy, stating that these medications are reducing the economic burden of obesity-related health issues. In an interview with NBC Nightly News, Jørgensen emphasized the costly impact of obesity in the U.S., which exceeds $400 billion annually, asserting that the company’s treatments are helping alleviate this financial burden. He dismissed accusations that Novo Nordisk operates as a drug cartel as “unfounded.” Also Read: Novo Nordisk’s Ozempic Might Be Among 2027 Medicare Price Negotiation Targets. Jørgensen’s comments come ahead of his scheduled testimony before a Senate committee next month, where he will address the pricing of Novo Nordisk’s widely popular diabetes and weight loss drugs. Senator Bernie Sanders, chair of the Health, ...


In The news